Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.36 USD | +5.66% | +5.00% | +21.30% |
05-14 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 20
Managers
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 27/05/14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/23 |
Jarrod Longcor
COO | Chief Operating Officer | 51 | 14/07/16 |
Shane Lea
PRN | Corporate Officer/Principal | - | 20/11/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 06/04/17 |
Douglas Swirsky
CHM | Chairman | 54 | 06/04/17 |
John Neis
BRD | Director/Board Member | 68 | 31/01/08 |
James V. Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Stefan Loren
BRD | Director/Board Member | 60 | 14/06/15 |
Director/Board Member | 55 | 23/06/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 320 | 0 | 0 | 88.19 % |
Stock B | 0 | 111 | 0 | 0 | |
Stock C | 0 | 1,237 | 0 | 0 | |
Stock D | 1 | 32,260,510 | 28,450,306 ( 88.19 %) | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.30% | 120M | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- CLRB Stock
- Company Cellectar Biosciences, Inc.